SULFAMETHOXAZOLE | N013664 | HOFFMANN LA ROCHE INC
| Trial | Phase | Status | Sponsor | Enrollment | Dates |
|---|---|---|---|---|---|
| Phase 1/2 | Active | University of Pennsylvania | 8 | 2019-03-27 → 2027-12-30 | |
| N/A | Active | Ann & Robert H Lurie Children's Hospital of Chicago | 93 | 2014-03 → 2025-08 | |
| Phase 1 | Recruiting | Astellas Institute for Regenerative Medicine | 42 | 2018-07-13 → 2026-06-30 | |
| Phase 2 | Recruiting | National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) | 130 | 2012-09-18 → 2027-01-01 | |
| Phase 4 | Recruiting | St. Joseph's Hospital and Medical Center, Phoenix | 116 | 2017-07-01 → 2019-07 | |
| Phase 4 | Completed | Radboud University Medical Center | 1,538 | 2018-04-03 → 2021-09-26 | |
| Phase 3 | Completed | Pfizer | 641 | 2012-10 → 2014-08 | |
| N/A | Completed | Medical College of Wisconsin | 67 | 2014-03-04 → 2018-04 | |
| Phase 1 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 48 | — → 1999-05 | |
| Phase 3 | Completed | University of Washington | 2 | 2006-05-01 → 2007-05-01 |
Source: ClinicalTrials.gov. Trials matched by ingredient name.
4 active API suppliers hold Drug Master Files for this ingredient.
Source: FDA Drug Master Files (fda.gov). Type II API DMFs matched by ingredient.
No patent or exclusivity listings for this strength.